Home › InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis
 

Keywords :   


InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis

2015-06-30 21:13:39| Appliances - Topix.net

June 30, 2015 - InDex Pharmaceuticals today announced the termination of a license agreement with Almirall S.A. relating to the drug candidate KappaproctA for the treatment of ulcerative colitis. Under the agreement, which was signed in March 2014, Almirall licensed exclusive rights to KappaproctA for the European market.

Tags: rights index european pharmaceuticals

Category:Consumer Goods and Services

Latest from this category

All news
22.11'Scammers sent courier to steal 4,000'
22.11Spain fines budget airlines including Ryanair 179m
22.11Formulating Biphasic and Triphasic Products
22.11Gatwick terminal evacuated due to security risk
22.1168% of US households have a smart TV, 46% have a streaming media player
22.11Reliance and Disney complete India JV transaction
22.11HbbTV Association appoints Service List Registry
22.11ocilion brings Prime Video and YouTube to its IPTV platform
Consumer Goods and Services »
23.11
23.11 WEEZER / maladroit 12\"
23.11
23.11 6'1ML REV-S
23.11speak up storys
23.11190mm LS0713FL
23.11That's Moulton
23.11SEED
More »